LiveMint-Author


Cipla, Roche may now spar over Valcyte Bhuma Shrivastava and C.H. Unnikrishnan 11:52 PM \| July 10,2008 Cipla’s drug may be called Valcept
SC issues stay order against appeal hearing Bhuma Shrivastava and C.H. Unnikrishnan 12:19 AM \| January 29,2008 Earlier, Madras HC had allowed the hearing without a tech member on IPAB, at the behest of Novartis AG
Bangalore company sees R&D scope in neglected diseases Bhuma Shrivastava and C.H. Unnikrishnan 02:13 AM \| October 13,2007 Advinus Therapeutics is bullish on undertaking research and developing drugs for tuberculosis, malaria
Glivec ruling spells bad news for 150 other patent filings in queue Bhuma Shrivastava and C.H. Unnikrishnan 02:12 AM \| August 08,2007 A large chunk of these have been filed by the local units of drug majors such as Merck, AstraZeneca and Pfizer
Mylan’s India unit key to Merck buy C.R. Sukumar, Bhuma Shrivastava and C.H. Unnikrishnan 07:36 AM \| May 14,2007 The deal may mark a global shift in pharma manufacturing strategies to tap the country’s low-cost edge


Cipla, Roche may now spar over Valcyte Bhuma Shrivastava and C.H. Unnikrishnan 11:52 PM \| July 10,2008 Cipla’s drug may be called Valcept
SC issues stay order against appeal hearing Bhuma Shrivastava and C.H. Unnikrishnan 12:19 AM \| January 29,2008 Earlier, Madras HC had allowed the hearing without a tech member on IPAB, at the behest of Novartis AG
Bangalore company sees R&D scope in neglected diseases Bhuma Shrivastava and C.H. Unnikrishnan 02:13 AM \| October 13,2007 Advinus Therapeutics is bullish on undertaking research and developing drugs for tuberculosis, malaria
Glivec ruling spells bad news for 150 other patent filings in queue Bhuma Shrivastava and C.H. Unnikrishnan 02:12 AM \| August 08,2007 A large chunk of these have been filed by the local units of drug majors such as Merck, AstraZeneca and Pfizer
Mylan’s India unit key to Merck buy C.R. Sukumar, Bhuma Shrivastava and C.H. Unnikrishnan 07:36 AM \| May 14,2007 The deal may mark a global shift in pharma manufacturing strategies to tap the country’s low-cost edge